<DOC>
	<DOCNO>NCT01359150</DOCNO>
	<brief_summary>A Randomized , Double Blind , Placebo Controlled Phase 2 Study To assess Immune Response Following Administration Influenza Pneumococcal Vaccines Subjects Rheumatoid Arthritis receive CP-690,550 Without background Methotrexate</brief_summary>
	<brief_title>A Study To Assess Immune Response Following Administration Of Influenza Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>The subject must meet American College Rheumatology ( ACR ) classification criterion diagnosis RA satisfy least four seven criterion . The subject must active disease screen baseline History document influenza pneumococcal infection within last 3 month . Receipt vaccine within 1 month prior initial study drug administration ( CP690,550 placebo CP690,550 ) . If subject receive influenza vaccine within 6 month pneumococcal vaccine within 5 year initial study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>